Paper Details

  1. Home
  2. Paper Details

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.

Author: BenboubkerLotfi, ChariAjai, ClemensPamela L, HellemansPeter, KaufmanJonathan L, LiuKevin, LuoMan, MastersonTara, MateosMaria-Victoria, MoreauPhilippe, NahiHareth, OriolAlbert, PlesnerTorben, San-MiguelJesus, UsmaniSaad Z, van de DonkNiels W C J

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigates the safety and pharmacokinetics of subcutaneously administered daratumumab in combination with rHuPH20 in patients with relapsed or refractory multiple myeloma (MM). The subcutaneous administration was well-tolerated, with PK concentrations and responses consistent with IV daratumumab.
Paper Details　
Original Abstract of the Article :
Daratumumab, a human monoclonal antibody targeting CD38, is approved as monotherapy and in combination regimens for patients with multiple myeloma (MM). Currently, daratumumab is administered IV. The phase 1b PAVO (MMY1004) study evaluated subcutaneously administered daratumumab in combination with ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754719/

データ提供：米国国立医学図書館（NLM）

Subcutaneous Delivery of Daratumumab in Relapsed or Refractory Multiple Myeloma

In the vast desert of medical research, we're always searching for new ways to treat diseases and improve patient outcomes. This study focuses on a new approach to delivering daratumumab, a medication used to treat multiple myeloma, a type of bone marrow cancer. Traditionally, daratumumab is administered intravenously, but this study explores the potential of subcutaneous delivery, which could offer a more convenient and less invasive option for patients.

Subcutaneous Delivery Shows Promise

The authors report that subcutaneous delivery of daratumumab, in combination with an enzyme called rHuPH20, was well-tolerated in patients with relapsed or refractory multiple myeloma. They found that the subcutaneous route achieved similar or even better serum concentrations of the medication compared to intravenous delivery. Furthermore, the study showed encouraging response rates, with 25% and 42.2% of patients achieving a response with the 1200-mg and 1800-mg subcutaneous doses, respectively. These findings suggest that subcutaneous delivery could potentially become a viable alternative to intravenous administration, offering patients a more convenient and comfortable experience.

Navigating the Shifting Sands of Treatment Options

This research is a step forward in the ongoing exploration of new treatment options for multiple myeloma. The potential benefits of subcutaneous delivery, such as increased patient comfort and convenience, are like finding a refreshing oasis in the desert. As we continue to explore the landscape of medical treatments, we may find that subcutaneous delivery becomes a more common and preferred approach for patients.

Dr.Camel's Conclusion

This study is like discovering a new oasis in the desert of multiple myeloma treatment. Subcutaneous delivery could provide a more comfortable and convenient option for patients, potentially improving their quality of life while maintaining therapeutic efficacy. It's exciting to see how this new approach could shape the future of multiple myeloma treatment.

Date :
  1. Date Completed 2020-01-27
  2. Date Revised 2021-02-02
Further Info :

Pubmed ID

31270103

DOI: Digital Object Identifier

PMC6754719

Related Literature

Article Analysis
・Effects of daratumumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.